Table 3.
Antimicrobial resistance observed from the 196 isolates and the isolates included in the 10 most frequent sequence types.
| Drug a | Number (%) of Resistant Isolates | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (n=196) |
B2 ST131 (n=23) |
A ST10 (n=9) |
B2 ST12 (n=8) |
B1 ST58 (n=5) |
D ST69 (n=13) |
B2 ST73 (n=21) |
C ST88 (n=12) |
B2 ST95 (n=10) |
B2 ST127 (n=7) |
B2 ST141 (n=14) |
|
| Ampicillin AM10 |
111
(56.6)b |
19
(82.6) |
4
(44.4) |
7
(87.5) |
5
(100) |
8
(61.5) |
6
(28.6) |
12
(100) |
3
(30) |
4
(57.1) |
3
(21.4) |
| Amoxicillin-Clavulanate AMC30 |
27 (13.8) |
7
(30.4) |
0 |
2
(25%) |
0 | 1 (7.7) |
1 (4.8) |
9
(75) |
0 | 0 | 0 |
| Cefazolin CZ30 |
27 (13.8) |
13
(56.5) |
0 | 0 | 1 (20) |
0 | 0 |
3
(25) |
0 | 0 | 0 |
| Cefuroxime CXM30 |
21 (10.7) |
7
(30.4) |
1 (11.1) |
0 | 1 (20) |
0 | 0 |
3
(25) |
0 | 0 | 0 |
| Cefotaxime CTX30 |
15 (7.7) |
6
(26.1) |
0 | 0 | 1 (20) |
0 | 0 | 0 | 0 | 0 | 0 |
| Ceftazidime CAZ30 |
3 (1.5) |
1 (4.3) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cefepime FED30 |
9 (4.6) |
2 (8.7) |
0 | 0 | 1 (20) |
0 | 0 | 1 (8.3) |
0 | 0 | 0 |
| Cefoxitin FOX30 |
7 (3.6) |
2 (8.7) |
0 | 0 | 0 | 0 | 0 | 1 (8.3) |
0 | 0 | 0 |
| Aztreonam ATM30 |
9 (4.6) |
2 (8.7) |
0 | 0 | 0 | 0 | 0 | 1 (8.3) |
0 | 0 | 0 |
| Gentamicin GM10 |
17 (3.6) |
4 (17.4) |
0 | 0 | 0 | 1 (7.7) |
0 |
5
(41.7) |
0 | 0 | 0 |
| Tobramycin NN10 |
13 (6.6) |
2 (8.7) |
0 | 0 | 0 | 1 (7.7) |
0 |
5
(41.7) |
0 | 0 | 0 |
| Doxycycline D30 |
60
(30.6) |
6
(26.1) |
3
(33.3) |
1 (12.5) |
3
(60) |
5 (38.5) | 4 (19) |
10
(83.3) |
1 (10) |
3
(42.9) |
0 |
| Chloramphenicol C30 |
23 (11.7) |
1 (4.3) |
1 (11.1) |
1 (12.5) |
0 | 1 (7.7) |
2 (9.5) |
9
(75) |
0 | 1 (14.3) |
0 |
| Nitrofurantoin FD300 |
2 (1.0) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nalidixic Acid NAL30 |
65
(33.2) |
17
(73.9) |
2
(22.2) |
3
(37.5) |
3
(60) |
7
(53.8) |
0 |
9
(75) |
2 (20) |
0 | 0 |
| Ciprofloxacin CIP5 |
42
(21.4) |
13
(56.5) |
1 (11.1) |
0 | 1 (20) |
0 | 0 |
9
(75) |
1 (10) |
0 | 0 |
| Trimethoprim-Sulfamethoxazole SXT25 |
57
(29.1) |
9
(39.1) |
2
(22.2) |
2
(25%) |
3
(60) |
7
(53.8) |
3 (14.3) |
9
(75) |
1 (10) |
1 (14.3) |
1 (7.1) |
| Multidrug resistance |
73
(37.2) |
18
(78.3) |
3
(33.3) |
1 (12.5) |
2
(40) |
6
(42.6) |
3 (14.3) |
10
(83.3) |
1 (10) |
2
(28.6) |
0 |
| ESBL | 13 (6.6) |
5
(21.7) |
0 | 0 | 1 (20.0) |
0 | 0 | 0 | 0 | 0 | 0 |
a None of the 196 isolates were resistant to the following antimicrobials: Imipenem (IMP10), amikacin (AN30), fosfomycin (FOS200) and colistin (CL10). b When the percentage is greater than 20%, it is highlighted in bold.